VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
MCRB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
MCRBSeres Therapeutics, Inc.
$3.79$37M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMCRBQuarterly Financials

Seres Therapeutics, Inc. (MCRB) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Seres Therapeutics, Inc. (MCRB) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

MCRB Income Statement

Quarterly statement

MCRB Income Statement

Seres Therapeutics, Inc. (MCRB) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q3'21
Sales/Revenue736K358K438K351K00000064K0126.47M-522K975K3.44M1.22M1.49M7.22M126.72M
Revenue Growth %-------100%--100%100%-93.44%-100%10300.74%-134.96%-86.5%-97.28%-76.9%-73.89%-58.89%8843.19%
Cost of Goods Sold0781K-13.8M13.35M1.06M3.53M5.13M1.4M019.49M0046.79M43.97M46.22M043.94M39.65M36.75M39.88M
COGS % of Revenue-218.16%-3151.83%3803.99%--------37%-8423.18%4740.51%-3613.08%2655.66%508.96%31.47%
Gross Profit736K-423K14.24M-13M-1.06M-3.53M-5.13M-1.4M0-19.49M64K079.68M-44.49M-45.24M3.44M-42.72M-38.16M-29.53M86.84M
Gross Margin %100%-118.16%3251.83%-3703.99%------100%-63%8523.18%-4640.51%100%-3513.08%-2555.66%-408.96%68.53%
Gross Profit Growth %169.5%88.01%377.75%-826%-81.91%-8112.5%--100%56.18%100.14%-100%286.52%-16.6%-53.21%-96.03%-39.19%-61.78%-304.37%6028.65%
Operating Expenses22.01M20.48M33.62M9.48M23.82M23.71M23.71M27.77M28.87M14.94M39.59M44.59M30.16M26.08M23.06M62.55M20.61M17.59M19.9M18.44M
OpEx % of Revenue2990.35%5721.79%7675.8%2699.72%------61859.38%-23.84%-4995.59%2365.33%1816.23%1694.57%1178.5%275.6%14.55%
Selling, General & Admin7.06M8.07M7.54M9.48M10.25M11.89M12.46M11.31M13.06M14.94M17.23M19.43M28.05M22.47M22.4M18.38M20.34M18.57M20.51M19.56M
SG&A % of Revenue959.38%2254.19%1721.23%2699.72%------26928.13%-22.18%-4304.6%2297.85%533.8%1672.29%1243.87%283.98%15.44%
Research & Development9.14M13.2M11.68M12.62M12.94M11.82M12.84M16.46M15.81M19.49M26.85M25.15M46.79M43.97M46.22M43.12M43.94M39.65M36.75M39.88M
R&D % of Revenue1241.98%3685.75%2667.58%3594.3%------41946.88%-37%-8423.18%4740.51%1251.92%3613.08%2655.66%508.96%31.47%
Other Operating Expenses1000K-781K1000K-1000K630K0-1000K00-1000K-1000K0-1000K-1000K-1000K1000K-1000K-1000K-1000K-1000K
Operating Income-21.27M-20.91M-19.38M-22.48M-24.88M-27.24M-28.84M-29.17M-28.87M-34.44M-39.53M-44.59M49.52M-70.57M-68.31M-59.11M-63.33M-55.75M-49.43M68.41M
Operating Margin %-2890.35%-5839.94%-4423.97%-6403.7%-------61759.38%-39.16%13518.77%-7005.85%-1716.23%-5207.65%-3734.16%-684.56%53.98%
Operating Income Growth %14.5%23.24%32.8%22.94%13.82%20.91%27.05%34.58%-158.3%51.2%42.13%24.57%178.21%-26.58%-38.18%-186.4%-31.54%-57.82%-176.19%328.06%
EBITDA-21.27M-20.13M-17.24M-21.42M-23.82M-26.16M-27.75M-27.77M-27.45M-32.88M-37.89M-42.9M51.05M-69.17M-66.68M-57.36M-61.64M-54.18M-47.88M69.9M
EBITDA Margin %-2890.35%-5621.79%-3936.53%-6101.99%-------59209.38%-40.37%13250.57%-6838.97%-1665.51%-5069.08%-3629%-663.07%55.16%
EBITDA Growth %10.7%23.07%37.87%22.86%13.22%20.44%26.77%35.28%-153.77%52.46%43.17%25.21%182.82%-27.66%-39.26%-182.06%-31.95%-60.06%-192.15%345.96%
D&A (Non-Cash Add-back)0781K2.13M1.06M1.06M1.08M1.08M1.4M1.42M1.56M1.63M1.68M1.53M1.4M1.63M1.75M1.69M1.57M1.55M1.49M
EBIT-21.27M-19.91M-15.34M8.2M-19.86M32.68M-15.64M-51.03M-26.2M-32.28M-37.22M-41.02M49.52M-70.57M-68.31M-58.27M-63.33M-55.75M-49.43M68.41M
Net Interest Income181K325K445K618K546K618K437K652K-2.22M-3.02M-2.06M-1.44M-1.46M-916K-466K-862K-1.11M-528K-253K-154K
Interest Income181K325K445K618K546K618K437K652K1.23M1.65M1.97M2.57M1.73M1.03M1.41M865K395K384K485K590K
Interest Expense000000003.45M4.66M4.03M4.01M3.19M1.95M1.88M1.73M1.5M912K738K744K
Other Income/Expense25.85M994K4.04M30.68M5.03M59.92M13.2M-21.86M2.67M1.53M-1.72M3.57M-2.97M-606K-489K-895K-1.41M-873K-569K-189K
Pretax Income4.58M-19.91M-15.34M8.2M-19.86M32.68M-15.64M-51.03M-26.2M-32.9M-41.25M-41.02M46.55M-71.17M-68.8M-60M-64.73M-56.62M-50M68.22M
Pretax Margin %622.42%-5562.29%-3501.14%2337.32%-------64450%-36.81%13634.87%-7056%-1742.22%-5323.6%-3792.63%-692.44%53.83%
Income Tax00000000000000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Income4.58M-19.91M-15.34M8.2M-19.86M32.68M-15.64M88.78M-32.87M-40.13M-41.25M-47.85M46.55M-71.17M-68.8M-60M-64.73M-56.62M-50M68.22M
Net Margin %622.42%-5562.29%-3501.14%2337.32%-------64450%-36.81%13634.87%-7056%-1742.22%-5323.6%-3792.63%-692.44%53.83%
Net Income Growth %123.07%-160.93%1.93%-90.76%39.6%181.43%62.09%285.51%-170.61%43.61%40.04%20.25%171.91%-25.7%-37.59%-187.96%-33.94%-59.66%-173.95%325.29%
Net Income (Continuing)4.58M-19.91M-15.34M8.2M-19.86M32.68M-15.64M-51.03M-26.2M-32.9M-41.25M-41.02M46.55M-71.17M-68.8M-60M-64.73M-56.62M-50M68.22M
Discontinued Operations00000001000K-1000K-1000K0-1000K00000000
Minority Interest00000000000000000000
EPS (Diluted)0.49-2.08-1.760.94-2.273.75-1.81-7.59-4.34-5.49-6.38-7.467.17-11.31-10.99-9.79-14.03-12.29-10.8814.37
EPS Growth %121.59%-155.47%2.76%112.38%47.7%168.31%71.64%-1.74%-160.53%51.46%41.92%23.83%151.09%7.96%-0.96%-168.16%-33.08%-58.56%-172.67%298.19%
EPS (Basic)0.49-2.08-1.770.94-2.273.76-1.81-7.59-4.34-5.49-6.38-7.467.29-11.31-10.99-9.79-14.03-12.29-10.8814.87
Diluted Shares Outstanding9.64M9.58M8.87M8.77M8.74M8.71M8.65M7.63M7.58M7.31M6.46M6.41M6.49M6.29M6.26M6.13M4.61M4.61M4.59M4.75M
Basic Shares Outstanding9.64M9.58M8.86M8.76M8.74M8.7M8.65M7.63M7.58M7.31M6.46M6.41M6.39M6.29M6.26M6.13M4.61M4.61M4.59M4.59M
Dividend Payout Ratio--------------------